Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441566 in Moderate to Severe Crohn's Disease
NCT06637631Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of balinatunfib in Crohn's disease (4 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving endoscopic response at 12 weeks. Started Dec 2024; status: terminated.
02
Drugs
balinatunfib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06637631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637631.